Treat-to-Target in RA Hits the Bull’s-eye


Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.

Reference1. Solomon DH, Yu Z, Katz JN, et al. Adverse events and resource use before and after treat to target in rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial. Arthritis Care Res. 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.